China's Kelun-Biotech licenses cancer treatment to Crescent Biopharma

SHANGHAI, Dec 5 (Reuters) - China's Sichuan Kelun-Biotech Biopharmaceutical (6990.HK) said Thursday night it would license an experimental cancer treatment out to U.S. drugmaker Crescent Biopharma, receiving $80 million upfront, up to another $1.25 billion if milestones are met, and tiered royalties on net sales. The licensed drug candidate, SKB105, is being evaluated for usage against solid